Skip to main content
. 2023 May 13;22:154. doi: 10.1186/s12936-023-04574-7

Table 5.

Summary of adverse events among children in the per-protocol population (PP) from southwest Nigeria with acute uncomplicated malaria treated with artemether–lumefantrine or pyronaridine–artesunate

Event All patients Artemether–lumefantrine Pyronaridine–artesunate p
N = 172 N = 87 N = 85
Adverse event from any cause 53 (30.8) 27 (31.0) 26 (30.6) 0.949
Fever 58 (34.1) 24 (27.9) 34 (40.5) 0.106
Chills and rigors 33 (19.6) 16 (18.6) 17 (20.5) 0.847
Anorexia 29 (17.1) 16 (18.6) 13 (15.5) 0.685
Cough 28 (16.6) 14 (16.3) 14 (16.9) 1.000
Headache 27 (16.0) 12 (14.1) 15 (17.9) 0.536
Fatigue 22 (12.9) 11 (12.6) 11 (13.1) 1.000
Pallor 17 (10.1) 9 (10.6) 8 (9.6) 1.000
Abdominal pains 12 (7.1) 5 (5.8) 7 (8.3) 0.563
Vomiting 11 (6.4) 6 (7.0) 5 (5.9) 1.000
Diarrhea 11 (6.4) 4 (4.6) 5 (6.0) 0.744
Palpitations 6 (3.5) 3 (3.4) 3 (3.6) 1.000
Nausea 6 (3.5) 3 (3.5) 3 (3.6) 1.000
Rashes 1 (0.6) 0 (0.00) 1 (1.2) 1.000

AL artemether–lumefantrine, PA pyronaridine–artesunate

*Chi square was used but with Yate correction where cell counts were less than 5